CDK4/6 inhibitors: advances in breast cancer management Podcast

CDK4/6 inhibitors: advances in breast cancer management

medthority
Join Dr Nadia Harbeck and Professor Alessandra Gennari in this podcast series on risk assessment and CDK4/6 inhibitors for the treatment of early breast cancer. This podcast is intended for registered Healthcare Professionals only. Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.
Episode 3: Explanations for the divergent results of PALLAS/PENELOPE-B and monarchE trials
In the third episode, Dr Nadia Harbeck and Professor Alessandra Gennari turn their attention to a discussion of the completed clinical trials for CDK4/6 inhibitors in early breast cancer, namely PALLAS and PENELOPE-B for palbociclib and monarchE for abemaciclib. The divergent results for palbociclib and abemaciclib were unexpected, particularly as both proved effective in the metastatic setting and are now standard therapy for this indication. Dr Harbeck and Professor Gennari share their views on the possible reasons for the different outcomes with palbociclib and abemaciclib in early breast cancer.
Sep 22, 2022
15 min
Episode 2: The RxPonder trial – identifying patients most likely to benefit from adjuvant therapy
Dr Nadia Harbeck and Professor Alessandra Gennari delve deeper into the RxPonder trial to explore the design and primary outcomes of the trial. Dr Harbeck and Professor Gennari engage in an insightful discussion of how RxPonder validated the use of the 21-gene expression assay as a tool to identify patients who could be spared chemotherapy.
Sep 22, 2022
9 min
Episode 1: The use of biomarkers to inform and individualise treatment decisions for patients with early breast cancer
In this first episode, Dr Nadia Harbeck and Professor Alessandra Gennari discuss ground-breaking trials, including the TailorX and RxPonder trials, that validated the use of gene expression assays to inform therapy decisions for patients with early breast cancer. Dr Harbeck also describes the ADAPT series, which combines gene expression assays with endocrine response to individualise therapy.
Sep 22, 2022
14 min